PCVX
Vaxcyte Inc
NASDAQ: PCVX · HEALTHCARE · BIOTECHNOLOGY
$61.46
+1.30% today
Updated 2026-10-28
Market cap
$10.01B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-7.62
Dividend yield
—
52W range
$40 – $91
Volume
2.4M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
3.2
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$117.30
+90.86%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy9 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.21 — safe zone
+ Debt/equity 0.04x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-532.46M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-223.49M | $-402.27M | $-463.93M | $-766.63M | $-284.30M |
| EPS | — | — | — | — | $-7.62 |
| Free cash flow | $-176.44M | $-364.67M | $-475.05M | $-669.29M | $-532.46M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-10-05 | WASSIL, JIM | M | 18,000 | — |
| 2026-10-05 | WASSIL, JIM | M | 18,000 | $5.35 |
| 2026-10-05 | COWAN, ELVIA | M | 19,000 | — |
Peer comparison
Smart narrative
Vaxcyte Inc trades at $61.46. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 3.21, it sits in the safe zone.
Frequently asked questions
What is Vaxcyte Inc's stock price?
Vaxcyte Inc (PCVX) trades at $61.46.
Is Vaxcyte Inc overvalued?
Vaxcyte Inc carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Vaxcyte Inc (PCVX)?
The 12-month analyst consensus target is $117.30, about 90.9% above the current $61.46. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Vaxcyte Inc's Altman Z-Score is 3.21, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-31.59%
Beta1.23
50D MA$61.08
200D MA$56.23
Shares out0.16B
Float0.14B
Short ratio—
Avg volume2.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—